Cargando…

Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?

Prostate cancer is one of the most heritable cancers in men, and recent genome-wide association studies have revealed numerous genetic variants associated with disease. The risk variants identified using case-control designs that compared unaffected individuals with all types of patients with prosta...

Descripción completa

Detalles Bibliográficos
Autor principal: Wiklund, Fredrik
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923737/
https://www.ncbi.nlm.nih.gov/pubmed/20667146
http://dx.doi.org/10.1186/gm166
_version_ 1782185536898727936
author Wiklund, Fredrik
author_facet Wiklund, Fredrik
author_sort Wiklund, Fredrik
collection PubMed
description Prostate cancer is one of the most heritable cancers in men, and recent genome-wide association studies have revealed numerous genetic variants associated with disease. The risk variants identified using case-control designs that compared unaffected individuals with all types of patients with prostate cancer show little or no ability to discriminate between indolent and fatal forms of this disease. This suggests different genetic components are involved in the initiation as compared with the prognosis of prostate cancer. Future studies contrasting patients with more and less aggressive disease, and exploring association with disease progression and prognosis, should be more effective in detecting genetic risk factors for prostate cancer outcome.
format Text
id pubmed-2923737
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29237372011-07-29 Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Wiklund, Fredrik Genome Med Review Prostate cancer is one of the most heritable cancers in men, and recent genome-wide association studies have revealed numerous genetic variants associated with disease. The risk variants identified using case-control designs that compared unaffected individuals with all types of patients with prostate cancer show little or no ability to discriminate between indolent and fatal forms of this disease. This suggests different genetic components are involved in the initiation as compared with the prognosis of prostate cancer. Future studies contrasting patients with more and less aggressive disease, and exploring association with disease progression and prognosis, should be more effective in detecting genetic risk factors for prostate cancer outcome. BioMed Central 2010-07-29 /pmc/articles/PMC2923737/ /pubmed/20667146 http://dx.doi.org/10.1186/gm166 Text en Copyright ©2010 BioMed Central Ltd
spellingShingle Review
Wiklund, Fredrik
Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
title Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
title_full Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
title_fullStr Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
title_full_unstemmed Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
title_short Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
title_sort prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923737/
https://www.ncbi.nlm.nih.gov/pubmed/20667146
http://dx.doi.org/10.1186/gm166
work_keys_str_mv AT wiklundfredrik prostatecancergenomicscanwedistinguishbetweenindolentandfataldiseaseusinggeneticmarkers